

BARDA Strategic Plan

HHS PHEMCE Stakeholders Workshop Arlington, VA September 25, 2008

Dr. Robin Robinson
Director
HHS/ASPR/BARDA



BARDA Strategic Plan 2008



BARDA Strategic Plan 2008

DRAFT

For Public Comment October 2008




U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES
ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE
BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY

BARDA Strategic Plan 2008 Contents

. IME	DA Introduction	
	Background.	
	2.1.1, BARDAs Role	
	2.1.2. BARDA History	
2.2	Meeting The Mission	
	2.2.1. BARDA Coab	
	2.2.2. Extramural & Intramural Programs	
	2.2.J. Accomplishments	
	2.2.4. Challenges	
23.	The BARDA Organization	
	BARDA's Role In The Public Health Emergency Countermeasures Enterprise	
	BARDA And The National Biodefense Medical Countermeasure Portfolio	
	A Portfolio Approach To Achieving Preparedness	
3.1	Setting Requirements	
3.2	Developing Medical Countermeasures	
	3.2.1. Current Development Efforts	
	3.2.2. Coordinating And Transitioning Development Programs Across Agencies	
	3.2.3. Early Development	
	3.2.4. Late Development	
	Establishing And Maintaining Stockpiles	
3.4.	Building Infrastructure For Manufacturing	1
3.5.	Innovation	1
Band	a Resources	
	Staff Profile.	
	Technical Capabilities	
	Program Capabilities	
7.	43.1. Program Management	
	4.3.2. Acculation Management System	
4.4	Officer 18	
	Funding	
4.6.		
	Communications & Stakeholder Engagement	
	Steps	
	Program Direction	
	Capabilities Development Plan	
5.3.		
5.4.	Massures Of Success	



BARDA Bridging Mission




$BARDA = (CBRN + PI + ED)^{MCM}$

- Coordination of PHEMCE Enterprise MCM Activities
- Advanced development
- Stockpile procurement & establishment
- Manufacturing infrastructure building
- Innovation



HHS Public Health Emergency Medical Countermeasures Enterprise

National Biodefense Science Board



PHEMCE COORDINATED PLANNING & EXECUTION












BARDA Partnerships





BARDA Lane Assignments

- BARDA receives from DNS WMD risk assessments
- BARDA with NIH & Enterprise members develops
 MCM requirements
- NIH supports MCM discovery, pre-clinical, and proof of concept Phase 1 studies
- BARDA supports MCM advanced development & commercialization towards FDA-licensure
- BARDA acquires MCMs for initial stockpiles until product licensure
- CDC/SNS acquires MCMs as licensed products



BARDA Bridges of Product Development & Acquisition

- Utilize robust product pipeline at early stage development
- Nurture MCM platform technology development for crossindication usage
- Foster focused and continued advanced development/commercialization of multiple product types
- Implement incremental milestone acquisitions for stockpile establishment with long term commitments
- Maintain multiproduct/multimanufacturer portfolio for sustainability & redundancy of preparedness/response
- Support supportive & ancillary product/services development & acquisition



BARDA Bridges of Product Manufacturing Infrastructure Building

- Retrofit existing facilities for maximal capacity and flexibility
- Support new facility building with multiproduct manufacturing capability
- Establish centers of excellence for product development & production for noncommercial products and industry partner assistance
- Establish network of formulation/fill-finish manufacturers for emergency production/distribution

Roadmap of N THREAT	MCM Progra	m Funding	and Ma	anagem 2005	ent 2006	2007	2008	2009	2010	2011	2012	201	13	2014	2015	2016	2017	2018	2019	2020
ITIKLAI	IVICIVI	Cell Based	4	2005	2000	2007	2000	2007	2010	2011	2012		- 1.6						2017	2020
Pandemic		Antigen Sparing									 	KE_	Y NIA	AID	NIAII	D/BARDA	BAR	DA		
		Mix n Match				_			<u> </u>			-					CNC		a Fut	uro CNC
	Vaccines	Next gen										1		tched bar nned prog	s indicate grams		SNS Delivery	Expecte Licensu		ure SNS elivery
		recombinant										<u> </u>			 					
		US H5N1 Vaccine Stockpile					+													
		Infrastructure				_					,,,,,,,,,,,					1				
Influenza		Advanced					22/2			\ \ \		<i>///</i>								
		Development Fed. Stockpile								,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	<u>\</u>			. D:						
		State Stockpile				-	+				Em	erg	ging	g Dis	ease	es				
	Diagnostics	POC diagnostic																		
	Ventilators	LIT diagnostic Ventilators																		
	&	Masks, Syringes,					•				,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,									
	Respirators Vaccines	Respirators 1st gen AVA								—										
Anthrax		2 nd gen rPA					////				,,,,,,	,,,,,,		_	→					
	Therapeutic	Monoclonal Ab		_								4	<u> </u>	•						
	s	Polyclonal Ab					U			<u> </u>	→									
	Vaccines	MVA Next gen Vx									<u> </u>	→		,,,,,,,,,	,,,,,,,,,,		,,,,,,,	,,,,,,,,,,	,,,,,,,,,	<u></u>
Smallpox	Therapeutic	Antiviral							,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		<u>.</u>		-							
	S	Antibody													,,,,,,,,,,,		,,,,,,, <u>,</u> ,,,,,		,,,,,,,,,,	<i></i>
	Therapeutic s	hBAT									<u> </u>								→	
Botulism		mAb ABE Small mol inhibitor									ı	<i></i>		,,,,,,,,,,,	,,,,,,,,,,		<i></i>	,,,,,,,,,,	,,,,,,,,,	1 →
		Hu Hyper Immune Single Horse											z	,,,,,,,,,,						<u>\</u> —
Viral Hemorrhagic Fever	Vaccines	multivalent													_			-		
	Therapeutic	Vaccine							<u>'</u>											
	S	Antiviral Immune therapy																_		
Broad	Therapeutic	Novel Broad				-														
Spectrum Ab	S	Spectrum Ab						Z				,,,,,,			-	+				
Chemical Agents	Therapeutic s	Nerve Agent Antidotes				=					,,,,,,,,,,,,	,,,,,,	,,,,,,,,		,,,,,,,,,,		,,,,,,,	•		
Agents Radiologic & Nuclear Agents	Therapeutic s	Dosimetry										/// V	,,,,,,,,		<u> </u>	+	_			
		Blocking Agent								ı										
		ARS/DEARE Decorporation			<u> </u>		7//											→		
		Decorporation													,,,, <u>,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,</u>				\sim	



BARDA Innovation

- Capability to focus support to academia & industry on new ways to make MCMs better in coordination with partners (NIH, DoD, CDC, Industry)
 - Animal models
 - Immune modulation
 - Immunity assessment
 - Analytical assays (potency assays)







BARDA Website



BARDA:

URL: www.hhs.gov/aspr/barda/

E-Mail: BARDA@hhs.gov

- BARDA Strategic Plan (Oct. 08)
- Upcoming Events
- Acquisitions
- BioShield
- Influenza Programs